Multiple sclerosis (relapsing-remitting) - fingolimod: final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on fingolimod for the treatment of relapsing-remitting multiple sclerosis and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 30 March 2012.
Multiple sclerosis (relapsing-remitting) - fingolimod: final appraisal determination document
Multiple sclerosis (relapsing-remitting) - fingolimod: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
Multiple sclerosis (relapsing-remitting) - fingolimod: consultee and commentator comments on the ACD
Multiple sclerosis (relapsing-remitting) - fingolimod: expert comments on the ACD
Multiple sclerosis (relapsing-remitting) - fingolimod: comments on the ACD received from the public through the NICE website
Multiple sclerosis (relapsing-remitting) - fingolimod: Evidence Review Group discussion of manufacturer's reponse to second ACD
This page was last updated: 15 March 2012